Schmidt H, Ehninger G, Dopfer R, Blaurock M, Naumann R, Einsele H, Haen M, Schüch K, Jaschonek K, Niethammer D
Department of Internal Medicine II, Children Hospital, Tübingen, Federal Rep[ublic of Germany.
Blut. 1988 Sep;57(3):139-42. doi: 10.1007/BF00320154.
Between 1982 and 1986 51 patients were treated with ciclosporin a (CSA) to prevent graft versus host disease (GvHD) after bone marrow transplantation (BMT). Major side effects of the drug were tremor, hypertension, hepatotoxicity and nephrotoxicity. Acute GvHD 0 degree to II degree occurred in 80% of our patients, and GvHD III degree and IV degree in 20% despite the use of CSA. Two to four days before the onset of GvHD, CSA serum levels were significantly lower on the average in patients who developed GvHD III degree and IV degree compared to the others. Our data indicate that plasma CSA concentrations higher than 250 ng/ml should be achieved to reduce the severity of GvHD after BMT.
